Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Net Cash Flow (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Net Cash Flow data on record, last reported at -$848000.0 in Q3 2025.

  • For Q3 2025, Net Cash Flow rose 41.68% year-over-year to -$848000.0; the TTM value through Sep 2025 reached -$2.7 million, up 82.52%, while the annual FY2024 figure was -$19.2 million, 1.71% up from the prior year.
  • Net Cash Flow reached -$848000.0 in Q3 2025 per MBRX's latest filing, down from -$159000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $71.1 million in Q1 2021 and bottomed at -$8.1 million in Q2 2022.
  • Average Net Cash Flow over 5 years is -$440052.6, with a median of -$5.1 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: soared 7412.99% in 2021, then plummeted 396.77% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$4.3 million in 2021, then crashed by 69.65% to -$7.3 million in 2022, then surged by 85.9% to -$1.0 million in 2023, then tumbled by 396.77% to -$5.1 million in 2024, then surged by 83.31% to -$848000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$848000.0 in Q3 2025, -$159000.0 in Q2 2025, and $3.4 million in Q1 2025.